Revance Therapeutics Inc (NAS:RVNC)
$ 2.67 -0.04 (-1.48%) Market Cap: 278.88 Mil Enterprise Value: 481.76 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Q4 2019 Revance Therapeutics Inc Earnings Call Transcript

Feb 24, 2020 / 09:30PM GMT
Release Date Price: $26.91 (-3.24%)
Operator

Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2019 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this call is being recorded today, February 24, 2020.

I would now like to turn the conference call over to Jeanie Herbert, Senior Director of Investor Relations and Corporate Communications for Revance. Please go ahead.

Jeanie D. Herbert
Revance Therapeutics, Inc. - Senior Director of IR & Corporate Communications

Thank you, Joelle. Joining us on the call today from Revance is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; Chief Operating Officer and President of R&D and Product Operations, Dr. Abhay Joshi; Chief Commercial Officer, Aesthetics & Therapeutics, Dustin Sjuts.

Earlier today, Revance released financial results for the fourth quarter and full year ended December 31, 2019. If you have not received this news release or would like to be added to the company's distribution list to receive future releases, please go to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot